

**Date:** January 16, 2026

To,  
Sr. General Manager  
Listing Department  
**BSE Limited**  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai – 400 001

**BSE Scrip Code: 544319**

To,  
Sr. General Manager  
Listing Department  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051

**NSE Symbol: SENORES**

**Sub.: Update on acquisition**

**Ref.: Our earlier intimation dated December 15, 2025**

Dear Sir/Madam,

We refer to our earlier intimation dated December 15, 2025, regarding the acquisition of 100% equity share capital of Apnar Pharma Private Limited ("**Target Company**") in terms of the Share Purchase Agreement ("**SPA**"), in two tranches. In this regard, we are pleased to inform that, the Company has completed the acquisition of 56,63,804 Equity Shares from existing shareholders of the Target Company, for a total consideration of ₹ 11,45,78,755/- (Rupees Eleven Crore Forty-Five Lakh Seventy-Eight Thousand Seven Hundred and Fifty-Five Only). Accordingly, the Company now holds 75% of the total paid-up equity share capital of the Target Company.

This transaction was completed on January 16, 2026. Further, the acquisition of the balance 25% Equity Shares is expected to be completed by Q2 of FY 2027, as communicated earlier vide our letter dated December 15, 2025. All other details of our letter dated December 15, 2025, remain unchanged.

This is for your information and records. The same is also being uploaded on the website of the Company at [www.senorespharma.com](http://www.senorespharma.com).

Thanking you.

**For Senores Pharmaceuticals Limited**

**Vinay Kumar Mishra**  
Company Secretary and Compliance Officer  
ICSI Membership No.: F11464

**Senores Pharmaceuticals Limited**

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,  
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: [info@senorespharma.com](mailto:info@senorespharma.com)

W: [www.senorespharma.com](http://www.senorespharma.com) | CIN No.: L24290GJ2017PLC100263